Navigation Links
CoLucid Pharmaceuticals and ILDONG Pharmaceutical Enter into a Distribution and Supply Agreement for Lasmiditan, a Novel Agent for Acute Migraine
Date:10/22/2013

DURHAM, N.C., Oct. 22, 2013 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., and ILDONG Pharmaceutical Co., Ltd., announced today that they have entered into a distribution and supply agreement for Lasmiditan in South Korea and Southeast Asia.

(Logo: http://photos.prnewswire.com/prnh/20130626/LA37332LOGO)

(Logo: http://photos.prnewswire.com/prnh/20130715/LA46582LOGO)

Under the terms of the agreement, CoLucid will receive upfront and milestone payments in addition to consideration for product supply in exchange for exclusive rights to ILDONG for development and commercialization of Lasmiditan in the territory. ILDONG will be responsible for the costs and activities related to development and regulatory approvals in the territory and will also participate in key registration trials as part of the global development plan. 

"We are very happy to announce the collaboration with ILDONG.  We look forward to working together with such a strong partner to bring Lasmiditan to the market to meet the many unmet needs of migraine sufferers," said Thomas P. Mathers, CEO of CoLucid.

ILDONG Pharma Chairman and CEO, Jung-chi Lee, Ph.D., commented, "We expect CoLucid's innovative drug, Lasmiditan, to be successfully developed under our partnership and be subsequently well positioned to perform in the Korean market and Southeast Asia in the near future.  We are sure that this will provide us a further opportunity to strengthen the relationship between our two companies."

ABOUT LASMIDITAN

Lasmiditan has been designed to deliver efficacy in acute migraine without the vasoconstrictor activity associated with previous generations of migraine therapies.  It selectively targets 5-HT1F receptors expressed in the trigeminal pathway.  Its novel chemical class and differentiated site and mechanism of action led to Lasmiditan's designation as a "ditan", a new drug class, by the INN.

CoLucid has successfully completed six clinical studies for Lasmiditan, including a Phase 2b study treating a single migraine attack in 391 patients, as well as a TQTc study.

Phase 3 development will address two major unmet needs in patients who are poorly served by currently available therapies:

  • Patients with risk factors for cardiovascular disease and those with cardiovascular disease
  • Patients who have not had adequate response to triptans

ABOUT MIGRAINE

Migraine is ranked as the seventh highest cause of global disability and in the top 10 causes of disability in 14 of 21 world regions studied, according to findings by the Global Burden of Disease Survey 2010 conducted by the World Health Organization. It is the leading cause of disability among neurological disorders.  Some 36 million Americans have migraine, more than have asthma or diabetes combined.  Migraine can be extremely disabling and costly, accounting for more than $20 billion in direct (e.g. doctor visits, medications) and indirect (e.g. missed work, lost productivity) expenses each year in the United States. The prevalence of migraine in Asia is approximately 9%, and in South Korea alone, it is 6%.  According to statistics available from the Health and Insurance Review Agency (HIRA), in 2012 more than 500,000 patients were diagnosed with migraine in Korea, with women accounting for 72% of these numbers.

ABOUT COLUCID PHARMACEUTICALS, INC.

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures. The company's pipeline includes Lasmiditan, a novel treatment for migraine headache. Lasmiditan is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies such as triptans.  Lasmiditan is a member of a novel drug class called "ditans" and, unlike triptans, penetrates the central nervous system (CNS) and selectively targets receptors expressed in the trigeminal pathway.  Lasmiditan does not interact with vasoconstrictor receptors on peripheral blood vessels which are activated by triptans. For more information, please visit CoLucid at www.colucid.com.

ABOUT ILDONG PHARMACEUTICAL CO., LTD.

ILDONG Pharmaceutical Co., Ltd., based in Seoul, Korea, is a leading Korean company focused on the development, manufacturing and marketing of pharmaceuticals and OTC products with sales of $317 million in 2012.  ILDONG, founded in 1941, is known to have leading expertise in various therapeutic categories, including neurology, antibiotics, gastrointestinal, anti-diabetics, cardiovascular and oncology.  For more information, visit ILDONG's website at www.ildong.com.


'/>"/>
SOURCE CoLucid Pharmaceuticals, Inc; ILDONG Pharmaceutical Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CoLucid Pharmaceuticals Details Phase 3 Development Strategy for Lasmiditan to Address Major Unmet Needs in Acute Migraine Therapy
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
9. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
10. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... CENTENNIAL, Colo. , Feb. 5, 2016  As ... about health. The multitude of recommended screenings and tests ... healthy aging a priority. However, for the majority of ... of proactive health planning. For the 37.5 million American ... time like the present to make hearing health a ...
(Date:2/5/2016)... 2016 Aethlon Medical, Inc. (Nasdaq: AEMD ), ... will be presenting at Source Capital Group,s 2016 Disruptive Growth ... at 2:15 p.m. ET on Wednesday, February 10, 2016.  ... taking place at 3:15 p.m. ET. http://www.aethlonmedical.com .  ... after the conclusion of the live event. The panel discussion ...
(Date:2/5/2016)... 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... underwritten secondary offering of 11,027,558 shares of its common ... of Blackstone and Goldman Sachs.  The shares are being ... $96.45 per share. The selling stockholders will receive all ... nor any of its directors, officers or other stockholders ...
Breaking Medicine Technology:
(Date:2/5/2016)... , ... February 05, 2016 , ... ... setting the stage for new clinical and scientific initiatives have all marked the ... she was appointed President and CEO of the nation’s oldest cancer center, Candace ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... College President George H. Van Allen have signed a joint enrollment and degree ... a seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. , The ...
(Date:2/5/2016)... ... 05, 2016 , ... The American public tends to feel uncomfortable about drinking ... regular municipal or well water. The recent experience with lead contaminated water in Flint, ... long way toward increasing public acceptance of recycled waste water as drinking water. ...
(Date:2/5/2016)... ... 05, 2016 , ... At its annual meeting held last week, the American ... National Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We ... Chambers , APDA President and CEO. “Pat has tirelessly served APDA since 2001 when ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the defenses of the day ... feature of patients with eating disorders is significant self-criticism, and consequently these patients experience ... are regarded as maladaptive means for coping with this unease, but also leads to ...
Breaking Medicine News(10 mins):